Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The FDA has approved empagliflozin (Jardiance) to improve glycemic control, along with diet and exercise, in patients with type 2 diabetes.
Approximately 26 million patients have been diagnosed with type 2 diabetes, and more than 90% of diabetes cases diagnosed in the United States are type 2 diabetes.
“Empagliflozin is a sodium glucose co-transport 2 (SGLT2) inhibitor. It works by blocking the re-absorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in diabetes who have elevated blood glucose levels,” wrote the agency in a press release.
http://www.clinicaladvisor.com/empagliflozin-approved-to-treat-diabetes/article/364230/
Approximately 26 million patients have been diagnosed with type 2 diabetes, and more than 90% of diabetes cases diagnosed in the United States are type 2 diabetes.
“Empagliflozin is a sodium glucose co-transport 2 (SGLT2) inhibitor. It works by blocking the re-absorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in diabetes who have elevated blood glucose levels,” wrote the agency in a press release.
http://www.clinicaladvisor.com/empagliflozin-approved-to-treat-diabetes/article/364230/
